Cipla Limited (BOM:500087)
1,360.00
+10.00 (0.74%)
At close: Oct 28, 2026
Cipla Revenue
Cipla had revenue of 73.68B INR in the quarter ending September 30, 2026, a decrease of -1.06%. This brings the company's total for the last twelve months to 279.89B, up 0.08% year-over-year. In the fiscal year ending March 31, 2026, Cipla had annual revenue of 278.28B with 2.06% growth.
Revenue (ttm)
279.89B
Revenue Growth
+0.08%
P/S Ratio
3.94
Revenue / Employee
8.92M
Employees
31,369
Market Cap
1.10T
Revenue by Geography
- India 126.80B 45.0%
- United States of America 68.72B 24.4%
- Rest of The World 43.25B 15.4%
- South Africa 42.85B 15.2%
Fiscal year ended Mar 31, 2026 See the full Cipla breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 278.28B | 5.60B | 2.06% |
| Mar 31, 2025 | 272.67B | 17.31B | 6.78% |
| Mar 31, 2024 | 255.37B | 29.77B | 13.20% |
| Mar 31, 2023 | 225.59B | 8.51B | 3.92% |
| Mar 31, 2022 | 217.08B | 25.87B | 13.53% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Aurobindo Pharma | 349.35B |
| Zydus Lifesciences | 285.92B |
| Cipla | 280.68B |
| Glenmark Pharmaceuticals | 177.37B |
| Mankind Pharma | 153.47B |
| Alkem Laboratories | 150.81B |
| Divi's Laboratories | 112.30B |
| Ipca Laboratories | 101.26B |
Cipla News
- 1 day ago - Cipla Transcript: Q2 26/27 - Transcripts
- 1 day ago - Cipla Quarterly report: Q2 2027 - Filings
- 1 day ago - Cipla Slides: Q2 2027 - Filings
- 1 day ago - India's Cipla misses quarterly profit view on muted US sales - Reuters
- 13 days ago - Indoco Remedies Share Price Quietly Does Something Most Mid-Cap Pharma Stocks Won’t - ABC Money
- 26 days ago - FDA cancels Pune Cipla facility's drug sale and distribution licences - The Times of India
- 26 days ago - Cipla's Pune Godown Loses Drug Licence Over 'Misbranding, Storage Violations' - NDTV
- 7 weeks ago - India's Cipla, China's Qilu partner for US launch of Merck's Keytruda biosimilar - Reuters